

UK NEQAS FOR H&I SCHEME 2B - CROSSMATCHING BY FLOW CYTOMETRY

T-CELL FLOW CYTOMETRY RESULTS OF SAMPLE 2B08/2014 (COMPARED TO LOCAL NEGATIVE CONTROL)

DESPATCHED ON 8TH JULY 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, -; B7, -; Cw7, -; DR15, -; DQ6, -

Summary of Results

Total tested	40	45	45	42
Positive	29	45	1	17
Negative	11	0	44	25
Not Tested	3	2	2	2
% Positive	72.5%	100.0%	2.2%	40.5%
% Negative	27.5%	0.0%	97.8%	59.5%

Consensus	Not Assessed	Positive	Negative	Not Assessed
HLA Antibody (Defined By CDC)	B57	A2, A28	Cw17	A3

Lab No.	Serum 1	Serum 2	Serum 3	Serum 4	Date Received	Date Tested	Comments
112	Positive	Positive	Negative	Positive	11-Jul	14-Jul	
114	Positive	Positive	Negative	Positive	09-Jul	10-Jul	
115	NT	NT	NT	NT	NT	NT	Late arrival of the samples
116	Positive	Positive	Negative	Positive	09-Jul	10-Jul	
117	Weak Positive	Positive	Negative	Equivocal	10-Jul	10-Jul	
118	Positive	Positive	Positive	Positive	09-Jul	09-Jul	
119	Positive	Positive	Negative	Negative	09-Jul	10-Jul	
120	Negative	Positive	Negative	Negative	10-Jul	11-Jul	
122	Positive	Positive	Negative	Positive	09-Jul	10-Jul	
126	Positive	Positive	Negative	Positive	09-Jul	09-Jul	
130	Positive	Positive	Negative	Positive	09-Jul	10-Jul	
136	Negative	Positive	Negative	Negative	09-Jul	10-Jul	
138	Positive	Positive	Negative	Positive	09-Jul	09-Jul	
142	Positive	Positive	Negative	Negative	09-Jul	10-Jul	
143	Positive	Positive	Negative	Positive	11-Jul	11-Jul	
144	Positive	Positive	Negative	Positive	10-Jul	11-Jul	
145	Positive	Positive	Negative	Negative	09-Jul	11-Jul	
147	Equivocal	Positive	Negative	Negative	11-Jul	11-Jul	
154	Positive	Positive	Negative	Positive	09-Jul	10-Jul	
157	Positive	Positive	Negative	Positive	09-Jul	09-Jul	
159	Positive	Positive	Negative	Equivocal	10-Jul	10-Jul	
160	Positive	Positive	Negative	Negative	09-Jul	10-Jul	
163	Positive	Positive	Negative	Positive	10-Jul	10-Jul	
164	Negative	Positive	Negative	Negative	09-Jul	10-Jul	
167	Positive	Positive	Negative	Positive	09-Jul	10-Jul	
169	Negative	Positive	Negative	Negative	09-Jul	10-Jul	
176	Positive	Positive	Negative	Negative	11-Jul	14-Jul	
186	Positive	Positive	Negative	Negative	09-Jul	09-Jul	
190	Equivocal	Positive	Negative	Negative	09-Jul	10-Jul	
191	Positive	Positive	Negative	Negative	10-Jul	10-Jul	
193	Positive	Positive	Negative	Positive	09-Jul	09-Jul	
194	Equivocal	Positive	Negative	Negative	09-Jul	09-Jul	
195	NT	NT	NT	NT	18-Jul	18-Jul	Late arrival of the samples
201	Negative	Positive	Negative	Negative	08-Jul	09-Jul	
202	Negative	Positive	Negative	Negative	09-Jul	09-Jul	
204	Positive	Positive	Negative	Positive	09-Jul	09-Jul	
209	Negative	Positive	Negative	Negative	09-Jul	11-Jul	
218	Positive	Positive	Negative	Positive	09-Jul	10-Jul	
220	Weak Positive	Positive	Negative	Negative	11-Jul	11-Jul	
227	NT	Positive	Negative	Negative	09-Jul	09-Jul	Serum 1: Result failure
235	Positive	Positive	Negative	Negative	10-Jul	10-Jul	
238	Equivocal	Positive	Negative	Negative	09-Jul	10-Jul	
245	Positive	Positive	Negative	Equivocal	09-Jul	10-Jul	
246	Negative	Positive	Negative	Negative	09-Jul	10-Jul	
252	Negative	Positive	Negative	Negative	11-Jul	11-Jul	
262	Negative	Positive	Negative	Negative	10-Jul	10-Jul	
283	Negative	Positive	Negative	Negative	09-Jul	09-Jul	

PLEASE NOTE: THE NEXT DISTRIBUTIONS IS ON 23RD SEPTEMBER 2014

UK NEQAS FOR H&I SCHEME 2B - CROSSMATCHING BY FLOW CYTOMETRY

B-CELL FLOW CYTOMETRY RESULTS OF SAMPLE 2B08/2014 (COMPARED TO LOCAL NEGATIVE CONTROL)

DESPATCHED ON 8TH JULY 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, -; B7, -; Cw7, -; DR15, -; DQ6, -

Summary of Results

Total tested	36	42	40	41
Positive	23	41	12	14
Negative	13	1	28	27
Not Tested	3	2	2	2
% Positive	63.9%	97.6%	30.0%	34.1%
% Negative	36.1%	2.4%	70.0%	65.9%

Consensus	Not Assessed	Positive	Not Assessed	Not Assessed
HLA Antibody (Defined By CDC)	B57	A2, A28	Cw17	A3

Lab No.	Serum 1	Serum 2	Serum 3	Serum 4	Date Received	Date Tested	Comments
112	Positive	Positive	Positive	Positive	11-Jul	14-Jul	
114	Negative	Positive	Negative	Negative	09-Jul	10-Jul	
115	NT	NT	NT	NT	NT	NT	Shipment received late in lab
116	Negative	Positive	Negative	Negative	09-Jul	10-Jul	
117	Positive	Positive	Positive	Equivocal	10-Jul	10-Jul	
118	Negative	Positive	Negative	Negative	09-Jul	09-Jul	
119	Positive	Positive	Negative	Negative	09-Jul	10-Jul	
120	Negative	Positive	Negative	Negative	10-Jul	11-Jul	
122	Positive	Positive	Positive	Positive	09-Jul	10-Jul	
126	Positive	Positive	Positive	Positive	09-Jul	09-Jul	
130	Positive	Positive	Positive	Positive	09-Jul	10-Jul	
142	Positive	Positive	Negative	Negative	09-Jul	10-Jul	
144	Positive	Positive	Negative	Negative	10-Jul	11-Jul	
145	Positive	Positive	Negative	Negative	09-Jul	11-Jul	
147	Positive	Positive	Positive	Negative	11-Jul	11-Jul	
154	Positive	Positive	Positive	Positive	09-Jul	10-Jul	
157	Positive	Positive	Negative	Positive	09-Jul	09-Jul	
159	Positive	Positive	Positive	Positive	10-Jul	10-Jul	
160	Positive	Positive	Positive	Positive	09-Jul	10-Jul	
163	Weak Positive	Positive	Negative	Weak Positive	10-Jul	10-Jul	
164	Positive	Positive	Negative	Negative	09-Jul	10-Jul	
167	Negative	Positive	Negative	Negative	09-Jul	10-Jul	
169	Negative	Positive	Negative	Negative	09-Jul	10-Jul	
176	Negative	Positive	Negative	Negative	11-Jul	14-Jul	
186	Negative	Positive	Negative	Negative	09-Jul	09-Jul	
190	Equivocal	Positive	Negative	Negative	09-Jul	10-Jul	
191	Negative	Positive	Negative	Negative	10-Jul	10-Jul	
193	Positive	Positive	Positive	Positive	09-Jul	09-Jul	
194	Positive	Positive	Equivocal	Positive	09-Jul	09-Jul	
195	NT	NT	NT	NT	18-Jul	18-Jul	Late arrival of the samples
201	Negative	Positive	Negative	Negative	08-Jul	09-Jul	
202	Negative	Negative	Negative	Negative	09-Jul	09-Jul	
204	Negative	Positive	Negative	Negative	09-Jul	09-Jul	
209	Equivocal	Positive	Equivocal	Negative	09-Jul	11-Jul	
218	Positive	Positive	Negative	Negative	09-Jul	10-Jul	
220	Weak Positive	Positive	Negative	Negative	11-Jul	11-Jul	
227	NT	Positive	Negative	Negative	09-Jul	09-Jul	
235	Positive	Positive	Negative	Positive	10-Jul	10-Jul	
238	Equivocal	Positive	Negative	Negative	09-Jul	10-Jul	
245	Equivocal	Positive	Negative	Negative	09-Jul	10-Jul	
246	Positive	Positive	Positive	Positive	09-Jul	10-Jul	
252	Positive	Positive	Positive	Positive	11-Jul	11-Jul	
262	Equivocal	Positive	Negative	Negative	10-Jul	10-Jul	
283	Negative	Positive	Negative	Negative	09-Jul	09-Jul	

PLEASE NOTE: THE NEXT DISTRIBUTIONS IS ON 23RD SEPTEMBER 2014

UK NEQAS FOR H&I SCHEME 2B - CROSSMATCHING BY FLOW CYTOMETRY

B-CELL FLOW CYTOMETRY RESULTS OF SAMPLE 2B08/2014 (COMPARED TO LOCAL NEGATIVE CONTROL)

DESPATCHED ON 8TH JULY 2014

Lab No.	Serum 1 cytometer reading	Serum 2 cytometer reading	Serum 3 cytometer reading	Serum 4 cytometer reading	Negative control (local)	Positive control (local)	Strong positive (local)	Weak positive (local)	Positive result value	Cytometer reading units	FCXM/NIBSC negative control used?
112	3.1	13.1	2.36	1.77	0.604	2.45			> 2.0 ratio	Log median channel	No
114	525	638	499	490	494	584			554 (494 + 60)	Median linear channel	No
115	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
116	4.61	14	3.46	3.89	6.17	34.9			Ratio > 1.7	Median log channel	No
117	20.53	72.25	19	-	9.32	314.43			Ratio (RFM) > 1.5	Median log channel	Yes
118	157.00	225.00	158.00	148.00	146.00	419.00			172 (146 + 26)	Median linear channel (MCI)	Yes
119	9.36	28.5	5.39	5.69	3.4	8.04			B-XM: ratio >1.7, B-line 1.5-1.7	MnIX	No
120	874	1934.5	870.5	571.5	459.5	20517			Negative control x 2	Median	No
122	100.5	438.5	70	66.5	27		159	87	3 SD	GeoMean linear values	Yes
126	592	749	544	521.5	416.5	857			> 80 median linear shift	Median linear channel	No
130	399	576	371	352	260	483			> 80		No
142	709	1288	555	466	550	3434			652.66, 3 SD	Median log channel	No
144	80.73	199.2	68.3	55.8	36.9	108.5					
	2.19	5.4	1.89	1.51	1	2.94			2	Ratio	
145	3.07	12	2.08	2.34	1.28	97.9			Med log ch test/med log ch neg > mean + 2 SD	Median log channel	
147	362	499	355	261	222	713			> 60 linear channel shift	Median linear channel	no
154	48.75	120.33	27.05	22.8	9.25	380.43			gMFI > 130% neg control + shape of the curve	gMFI	No
157	259	442	124	249	208	561			243 (neg + 35)	Median linear channel	No
159	418	590	391	354	289	640			60 linear channel shift (> 349 MLC)	Mean linear channel	No
160	178	837	169	124	25.4	652			> 64.1 (negative + 3 SD)	Mean linear channel	No
163	2.20	4.80	1.50	1.70	1.00	1.9			1.7	Geomean log channel (serum/neg control)	Yes
164	51.1	167	36	35	20	730			Neg control x 2.5		No
167	63	159	27	44	41	1633			2 SD	Median log channel	No
169	18.82	32.27	16.44	16.76	13.36	60.7					
	140	241	123	125		454			NR = (MFI serum/MFI neg serum) x100	Mean log channel	No
									Pos >200		
176	SI 0.25	0.63	0.1	0.04	0				SI ≥ 0.30		No
	MESF 36.602	84.625	25.646	21.635	16.694						
186	1.41	4.22	1.39	1.26	1.36	9.59			Twice the local negative	Mean fluorescence intensity - log channel	No
190	157.33	494.67	117.67	113.70	59.73	466			Ratio sample/negative > 2.5	Mean linear channel	No
191	-33	70	-56	-41	0	317			MFI > 10	MFI	No
193	122.02	329.56	96.02	92.03	29.02	459.34			2.5 x negative control	Geomean	No
194	49.1	73	181	40.4	12	192			2 SD	Median log channel	No
195	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
201	3.38	8.87	5.37	3.24	3.33	86.4			X-mean ≥2.5	X-mean	No
202	6.2	7.8	5.1	4	4.8	90.4			8% above the local neg control	Linear scale	
204	10.9	25.9	5.08	6.08	5.8	27.3			11.6 = 2 x loc neg ctrl	Mean log channel	No
209	Ratio -	10.22	-	1.61	443	985			> 1.69 Ratio	GeoMean log channel	Yes
218	4859	8756	1889	2702	3238.5	4792			1905 x 1.7 = 3238.5	Geometric MFI	No
220	10.76	15.87	8.99	9.57	9.79		271.38	65.50	2 SD		No
227	-	9.91	3.63	3.83	3.13	75.3			6.26 (2 x local negative control)	Mean log channel	No
235	5.14	8.33	3.61	5.85	1.9	115.2			± 4 SD	Median log channel	No
238	1888	7213	1388	1213	1120	23639			MESF seru/MESF negative control	MESF	No
245	18.3	60.3	13.3	9.3	33.7	54			20 linear channel shift	Linear channel shift	Yes
246	93.7%	91.2%	79.6%	72.1%	<1.0%	93.7%			30%		No
252	1.66	4.19	1.49	1.22	262	457			xm median channel/neg median channel	Median channel ratio	No
262	Ratio -	4.6	-	-	2157	40547			Ratio sample/neg > 2, lysis > 12%	Median log channel	No
	Lysis -	82%	-	-							
283	-131.79	773.14	91.7	-220.51	881.68	556.51			140 (channel shift)	Channel shift	No